TGOPF:OTC-3i Group plc (USD)

COMMON STOCK | |

Last Closing

USD 46.89

Change

0.00 (0.00)%

Market Cap

USD 45.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

3i Group plc is a private equity firm specializing in mature companies, growth capital, middle markets, infrastructure, and management leveraged buyouts and buy-ins. The firm also provides infrastructure financing and debt management. For debt management, it invests in senior and mezzanine corporate debt in typically large and private companies in United Kingdom, Europe, Asia, and North America. It makes private equity investments in business and technology services, financial services, consumer and private label, software and service, healthcare, consumption and distribution, media and telecom, renewable energy, wind, and industrial technology sector. Within business and technology services, the firm seeks to invest in sub sectors such as testing, inspection and certification; intelligent outsourcing, BPO and consultancy; human capital including staffing, governance, risk and compliance, services to pharmaceutical companies, vertical application software, education and training businesses; facilities management; support services to industrial sectors such as oil and gas and utilities; human resources outsourcing and advising; recruitment; logistics and infrastructure support services including distribution, waste, and rental. In the consumer sector, it focuses on, multi-unit roll out, omni-channel propositions, niche branded consumer goods, polarization, health and wellness, ageing population, millennials, consumer goods; e-commerce; retail; food and drinks; private label CMO and leisure. In the healthcare sector, the firm focuses on outsourced medical device manufacturing & services, outsourced pharmaceutical manufacturing & services, bioprocessing supply chain, life science tools and diagnostics, wellness & consumer health products, personalized medicine, pharmaceuticals and biotechnology including specialty pharma, generics or OTC, drug delivery, and animal health; healthcare services including activities such as elderly and specialty care, including caring for people in their own homes, in hospital and in co

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-02 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
PSZKF Powszechna Kasa Oszczednosci B..

N/A

USD 13.13B
SHZHY Shenzhou International Group H..

N/A

USD 11.89B
PSHZF Pershing Square Holdings Ltd

N/A

USD 11.00B
IDKOF Idemitsu Kosan Co.Ltd

N/A

USD 9.59B
EFGSF Eiffage SA

N/A

USD 8.15B
SKSUF Sekisui Chemical Co. Ltd

N/A

USD 7.67B
AZRGF Azrieli Group Ltd

N/A

USD 7.63B
RUMOF Rumo S.A

N/A

USD 7.02B
DFKCY Daifuku Co. Ltd

N/A

USD 6.64B
PLLIF Pirelli & C. S.p.A

N/A

USD 6.40B

ETFs Containing TGOPF

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.52% N/A N/A 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.52% N/A N/A 63% D
Trailing 12 Months  
Capital Gain 45.71% N/A N/A 84% B
Dividend Return 1.36% N/A N/A 14% F
Total Return 47.07% N/A N/A 83% B
Trailing 5 Years  
Capital Gain 214.70% N/A N/A 93% A
Dividend Return 18.60% N/A N/A 53% F
Total Return 233.30% N/A N/A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 39.97% 76% C+ 74% C
Dividend Return 43.27% 77% C+ 73% C
Total Return 3.30% 52% F 60% D-
Risk Return Profile  
Volatility (Standard Deviation) 38.66% 56% F 61% D-
Risk Adjusted Return 111.94% 99% N/A 99% N/A
Market Capitalization 45.40B N/A N/A 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike